Florida Senate - 2026 COMMITTEE AMENDMENT
Bill No. SB 432
Ì304338/Î304338
LEGISLATIVE ACTION
Senate . House
.
.
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
The Committee on Fiscal Policy (Yarborough) recommended the
following:
1 Senate Amendment (with title amendment)
2
3 Delete everything after the enacting clause
4 and insert:
5 Section 1. Effective July 1, 2026, paragraph (c) of
6 subsection (1) of section 893.03, Florida Statutes, is amended
7 to read:
8 893.03 Standards and schedules.—The substances enumerated
9 in this section are controlled by this chapter. The controlled
10 substances listed or to be listed in Schedules I, II, III, IV,
11 and V are included by whatever official, common, usual,
12 chemical, trade name, or class designated. The provisions of
13 this section shall not be construed to include within any of the
14 schedules contained in this section any excluded drugs listed
15 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
16 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
17 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
18 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
19 Anabolic Steroid Products.”
20 (1) SCHEDULE I.—A substance in Schedule I has a high
21 potential for abuse and has no currently accepted medical use in
22 treatment in the United States and in its use under medical
23 supervision does not meet accepted safety standards. The
24 following substances are controlled in Schedule I:
25 (c) Unless specifically excepted or unless listed in
26 another schedule, any material, compound, mixture, or
27 preparation that contains any quantity of the following
28 hallucinogenic substances or that contains any of their salts,
29 isomers, including optical, positional, or geometric isomers,
30 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
31 salts of isomers, homologues, nitrogen-heterocyclic analogs,
32 esters, or ethers, if the existence of such salts, isomers, and
33 salts of isomers is possible within the specific chemical
34 designation or class description:
35 1. Alpha-Ethyltryptamine.
36 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
37 oxazoline).
38 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
39 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
40 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
41 6. Bufotenine.
42 7. Cannabis.
43 8. Cathinone.
44 9. DET (Diethyltryptamine).
45 10. 2,5-Dimethoxyamphetamine.
46 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
47 12. DMT (Dimethyltryptamine).
48 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
49 analog of phencyclidine).
50 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
51 15. N-Ethylamphetamine.
52 16. Fenethylline.
53 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
54 18. Ibogaine.
55 19. LSD (Lysergic acid diethylamide).
56 20. Mescaline.
57 21. Methcathinone.
58 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
59 23. PMA (4-Methoxyamphetamine).
60 24. PMMA (4-Methoxymethamphetamine).
61 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
62 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
63 27. MDA (3,4-Methylenedioxyamphetamine).
64 28. JB-336 (N-Methyl-3-piperidyl benzilate).
65 29. N,N-Dimethylamphetamine.
66 30. Parahexyl.
67 31. Peyote.
68 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
69 analog of phencyclidine).
70 33. Psilocybin.
71 34. Psilocyn.
72 35. Salvia divinorum, except for any drug product approved
73 by the United States Food and Drug Administration which contains
74 Salvia divinorum or its isomers, esters, ethers, salts, and
75 salts of isomers, esters, and ethers, if the existence of such
76 isomers, esters, ethers, and salts is possible within the
77 specific chemical designation.
78 36. Salvinorin A, except for any drug product approved by
79 the United States Food and Drug Administration which contains
80 Salvinorin A or its isomers, esters, ethers, salts, and salts of
81 isomers, esters, and ethers, if the existence of such isomers,
82 esters, ethers, and salts is possible within the specific
83 chemical designation.
84 37. Xylazine, except for a xylazine animal drug product
85 approved by the United States Food and Drug Administration and
86 the use of which conforms to the approved application or is
87 authorized under 21 U.S.C. s. 360b(a)(4). The manufacture,
88 importation, distribution, prescribing, or sale of xylazine for
89 human use is not subject to this exception.
90 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
91 (Thiophene analog of phencyclidine).
92 39. 3,4,5-Trimethoxyamphetamine.
93 40. Methylone (3,4-Methylenedioxymethcathinone).
94 41. MDPV (3,4-Methylenedioxypyrovalerone).
95 42. Methylmethcathinone.
96 43. Methoxymethcathinone.
97 44. Fluoromethcathinone.
98 45. Methylethcathinone.
99 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
100 yl)phenol) and its dimethyloctyl (C8) homologue.
101 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
102 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
103 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
104 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
105 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
106 naphthoyl)indole).
107 51. BZP (Benzylpiperazine).
108 52. Fluorophenylpiperazine.
109 53. Methylphenylpiperazine.
110 54. Chlorophenylpiperazine.
111 55. Methoxyphenylpiperazine.
112 56. DBZP (1,4-Dibenzylpiperazine).
113 57. TFMPP (Trifluoromethylphenylpiperazine).
114 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
115 Methylenedioxy-N-methylbutanamine).
116 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
117 60. 5-Hydroxy-N-methyltryptamine.
118 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
119 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
120 63. Methyltryptamine.
121 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
122 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
123 66. Tyramine (4-Hydroxyphenethylamine).
124 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
125 68. DiPT (N,N-Diisopropyltryptamine).
126 69. DPT (N,N-Dipropyltryptamine).
127 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
128 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
129 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
130 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
131 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
132 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
133 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
134 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
135 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
136 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
137 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
138 81. Butylone (3,4-Methylenedioxy-alpha
139 methylaminobutyrophenone).
140 82. Ethcathinone.
141 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
142 84. Naphyrone (Naphthylpyrovalerone).
143 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
144 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
145 87. 3,4-Methylenedioxy-propiophenone.
146 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
147 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
148 90. 3,4-Methylenedioxy-N-acetylcathinone.
149 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
150 92. 3,4-Methylenedioxy-N-acetylethcathinone.
151 93. Bromomethcathinone.
152 94. Buphedrone (alpha-Methylamino-butyrophenone).
153 95. Eutylone (3,4-Methylenedioxy-alpha
154 ethylaminobutyrophenone).
155 96. Dimethylcathinone.
156 97. Dimethylmethcathinone.
157 98. Pentylone (3,4-Methylenedioxy-alpha
158 methylaminovalerophenone).
159 99. MDPPP (3,4-Methylenedioxy-alpha
160 pyrrolidinopropiophenone).
161 100. MDPBP (3,4-Methylenedioxy-alpha
162 pyrrolidinobutyrophenone).
163 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
164 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
165 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
166 (Benocyclidine).
167 104. F-MABP (Fluoromethylaminobutyrophenone).
168 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
169 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
170 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
171 108. Me-EABP (Methylethylaminobutyrophenone).
172 109. Etizolam.
173 110. PPP (Pyrrolidinopropiophenone).
174 111. PBP (Pyrrolidinobutyrophenone).
175 112. PVP (Pyrrolidinovalerophenone) or
176 (Pyrrolidinopentiophenone).
177 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
178 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
179 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
180 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
181 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
182 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
183 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
184 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
185 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
186 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
187 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
188 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
189 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
190 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
191 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
192 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
193 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
194 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
195 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
196 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
197 ol).
198 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
199 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
200 methanol).
201 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
202 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
203 1,4-dione).
204 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
205 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
206 undecanamide).
207 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
208 undecanamide).
209 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
210 methyloctan-2-yl)phenol).
211 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
212 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
213 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
214 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
215 methoxyphenylacetyl)indole).
216 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
217 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
218 naphthalenylmethanone).
219 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
220 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
221 naphthalenylmethanone).
222 143. Pentedrone (alpha-Methylaminovalerophenone).
223 144. Fluoroamphetamine.
224 145. Fluoromethamphetamine.
225 146. Methoxetamine.
226 147. Methiopropamine.
227 148. Methylbuphedrone (Methyl-alpha
228 methylaminobutyrophenone).
229 149. APB ((2-Aminopropyl)benzofuran).
230 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
231 151. UR-144 (1-Pentyl-3-(2,2,3,3
232 tetramethylcyclopropanoyl)indole).
233 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
234 tetramethylcyclopropanoyl)indole).
235 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
236 tetramethylcyclopropanoyl)indole).
237 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
238 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
239 iodobenzoyl)indole).
240 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
241 carboxamide).
242 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
243 cyclohexylcarbamate).
244 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
245 cyclohexyl ester).
246 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
247 benzoxazin-4-one).
248 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
249 161. 2C-H (2,5-Dimethoxyphenethylamine).
250 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
251 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
252 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
253 methoxybenzyl)]phenethylamine).
254 165. MDMA (3,4-Methylenedioxymethamphetamine).
255 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
256 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
257 carboxylate).
258 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
259 carboxylate).
260 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
261 3-carboxamide).
262 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
263 pentylindazole-3-carboxamide).
264 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
265 (4-fluorobenzyl)indazole-3-carboxamide).
266 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
267 1-pentylindazole-3-carboxamide).
268 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
269 yl)-1-(fluoropentyl)indole-3-carboxamide).
270 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
271 methoxybenzyl)]phenethylamine).
272 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
273 methoxybenzyl)]phenethylamine).
274 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
275 (cyclohexylmethyl)indazole-3-carboxamide).
276 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
277 carboxylate).
278 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
279 3-carboxamide).
280 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
281 (fluoropentyl)indazole-3-carboxamide).
282 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
283 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
284 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
285 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
286 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
287 hexahydrobenzo[c]chromen-1-ol).
288 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
289 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
290 hexahydrobenzo[c]chromen-1-ol).
291 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
292 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
293 diol).
294 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
295 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
296 tetrahydro-6aH-benzo[c]chromen-1-ol).
297 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
298 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
299 187. MAPB ((2-Methylaminopropyl)benzofuran).
300 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
301 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
302 190. Synthetic Cannabinoids.—Unless specifically excepted
303 or unless listed in another schedule or contained within a
304 pharmaceutical product approved by the United States Food and
305 Drug Administration, any material, compound, mixture, or
306 preparation that contains any quantity of a synthetic
307 cannabinoid found to be in any of the following chemical class
308 descriptions, or homologues, nitrogen-heterocyclic analogs,
309 isomers (including optical, positional, or geometric), esters,
310 ethers, salts, and salts of homologues, nitrogen-heterocyclic
311 analogs, isomers, esters, or ethers, whenever the existence of
312 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
313 ethers, salts, and salts of isomers, esters, or ethers is
314 possible within the specific chemical class or designation.
315 Since nomenclature of these synthetically produced cannabinoids
316 is not internationally standardized and may continually evolve,
317 these structures or the compounds of these structures shall be
318 included under this subparagraph, regardless of their specific
319 numerical designation of atomic positions covered, if it can be
320 determined through a recognized method of scientific testing or
321 analysis that the substance contains properties that fit within
322 one or more of the following categories:
323 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
324 naturally contained in a plant of the genus Cannabis, the
325 synthetic equivalents of the substances contained in the plant
326 or in the resinous extracts of the genus Cannabis, or synthetic
327 substances, derivatives, and their isomers with similar chemical
328 structure and pharmacological activity, including, but not
329 limited to, Delta 9 tetrahydrocannabinols and their optical
330 isomers, Delta 8 tetrahydrocannabinols and their optical
331 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
332 isomers, or any compound containing a tetrahydrobenzo[c]chromene
333 structure with substitution at either or both the 3-position or
334 9-position, with or without substitution at the 1-position with
335 hydroxyl or alkoxy groups, including, but not limited to:
336 (I) Tetrahydrocannabinol.
337 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
338 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
339 ol).
340 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
341 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
342 ol).
343 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
344 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
345 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
346 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
347 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
348 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
349 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
350 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
351 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
352 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
353 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
354 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
355 (X) Parahexyl.
356 b. Naphthoylindoles, Naphthoylindazoles,
357 Naphthoylcarbazoles, Naphthylmethylindoles,
358 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
359 compound containing a naphthoylindole, naphthoylindazole,
360 naphthoylcarbazole, naphthylmethylindole,
361 naphthylmethylindazole, or naphthylmethylcarbazole structure,
362 with or without substitution on the indole, indazole, or
363 carbazole ring to any extent, whether or not substituted on the
364 naphthyl ring to any extent, including, but not limited to:
365 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
366 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
367 naphthoyl)indole).
368 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
369 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
370 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
371 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
372 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
373 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
374 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
375 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
376 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
377 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
378 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
379 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
380 naphthoyl)indole).
381 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
382 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
383 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
384 naphthoyl)indole).
385 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
386 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
387 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
388 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
389 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
390 naphthylmethyl]indole).
391 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
392 naphthoyl)indole).
393 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
394 naphthoyl)indole).
395 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
396 naphthoyl)indole).
397 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
398 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
399 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
400 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
401 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
402 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
403 naphthoyl)indole).
404 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
405 naphthoyl)indole).
406 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
407 naphthoyl)indole).
408 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
409 naphthoyl)indole).
410 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
411 naphthoyl)indole).
412 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
413 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
414 naphthoyl)indazole).
415 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
416 naphthoyl)indole).
417 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
418 naphthoyl)indole).
419 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
420 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
421 naphthoyl)carbazole).
422 c. Naphthoylpyrroles.—Any compound containing a
423 naphthoylpyrrole structure, with or without substitution on the
424 pyrrole ring to any extent, whether or not substituted on the
425 naphthyl ring to any extent, including, but not limited to:
426 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
427 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
428 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
429 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
430 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
431 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
432 naphthoyl)pyrrole).
433 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
434 naphthoyl)pyrrole).
435 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
436 naphthoyl)pyrrole).
437 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
438 naphthoyl)pyrrole).
439 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
440 naphthoyl)pyrrole).
441 d. Naphthylmethylenindenes.—Any compound containing a
442 naphthylmethylenindene structure, with or without substitution
443 at the 3-position of the indene ring to any extent, whether or
444 not substituted on the naphthyl ring to any extent, including,
445 but not limited to, JWH-176 (3-Pentyl-1
446 (naphthylmethylene)indene).
447 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
448 compound containing a phenylacetylindole or phenylacetylindazole
449 structure, with or without substitution on the indole or
450 indazole ring to any extent, whether or not substituted on the
451 phenyl ring to any extent, including, but not limited to:
452 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
453 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
454 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
455 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
456 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
457 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
458 (VII) Cannabipiperidiethanone.
459 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
460 methoxyphenylacetyl)indole).
461 f. Cyclohexylphenols.—Any compound containing a
462 cyclohexylphenol structure, with or without substitution at the
463 5-position of the phenolic ring to any extent, whether or not
464 substituted on the cyclohexyl ring to any extent, including, but
465 not limited to:
466 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
467 yl)phenol).
468 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
469 homologue).
470 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
471 methyloctan-2-yl)phenol).
472 g. Benzoylindoles and Benzoylindazoles.—Any compound
473 containing a benzoylindole or benzoylindazole structure, with or
474 without substitution on the indole or indazole ring to any
475 extent, whether or not substituted on the phenyl ring to any
476 extent, including, but not limited to:
477 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
478 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
479 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
480 iodo-5-nitrobenzoyl)indole).
481 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
482 methoxybenzoyl)indole).
483 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
484 iodobenzoyl)indole).
485 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
486 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
487 methoxybenzoyl)indole).
488 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
489 3-(4-methoxybenzoyl)indole).
490 h. Tetramethylcyclopropanoylindoles and
491 Tetramethylcyclopropanoylindazoles.—Any compound containing a
492 tetramethylcyclopropanoylindole or
493 tetramethylcyclopropanoylindazole structure, with or without
494 substitution on the indole or indazole ring to any extent,
495 whether or not substituted on the tetramethylcyclopropyl group
496 to any extent, including, but not limited to:
497 (I) UR-144 (1-Pentyl-3-(2,2,3,3
498 tetramethylcyclopropanoyl)indole).
499 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
500 tetramethylcyclopropanoyl)indole).
501 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
502 tetramethylcyclopropanoyl)indole).
503 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
504 tetramethylcyclopropanoyl)indole).
505 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
506 tetramethylcyclopropanoyl)indole).
507 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
508 tetramethylcyclopropanoyl)indole).
509 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
510 tetramethylcyclopropanoyl)indole).
511 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
512 tetramethylcyclopropanoyl)indazole).
513 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
514 tetramethylcyclopropanoyl)indole).
515 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
516 tetramethylcyclopropanoyl)indole).
517 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
518 carboxamides, and Adamantylindazole carboxamides.—Any compound
519 containing an adamantoyl indole, adamantoyl indazole, adamantyl
520 indole carboxamide, or adamantyl indazole carboxamide structure,
521 with or without substitution on the indole or indazole ring to
522 any extent, whether or not substituted on the adamantyl ring to
523 any extent, including, but not limited to:
524 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
525 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
526 3-carboxamide).
527 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
528 carboxamide).
529 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
530 adamantoyl)indole).
531 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
532 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
533 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
534 adamantoyl)indole).
535 j. Quinolinylindolecarboxylates,
536 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
537 and Quinolinylindazolecarboxamides.—Any compound containing a
538 quinolinylindole carboxylate, quinolinylindazole carboxylate,
539 isoquinolinylindole carboxylate, isoquinolinylindazole
540 carboxylate, quinolinylindole carboxamide, quinolinylindazole
541 carboxamide, isoquinolinylindole carboxamide, or
542 isoquinolinylindazole carboxamide structure, with or without
543 substitution on the indole or indazole ring to any extent,
544 whether or not substituted on the quinoline or isoquinoline ring
545 to any extent, including, but not limited to:
546 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
547 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
548 carboxylate).
549 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
550 carboxylate).
551 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
552 carboxylate).
553 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
554 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
555 3-carboxylate).
556 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
557 3-carboxylate).
558 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
559 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
560 carboxamide).
561 k. Naphthylindolecarboxylates and
562 Naphthylindazolecarboxylates.—Any compound containing a
563 naphthylindole carboxylate or naphthylindazole carboxylate
564 structure, with or without substitution on the indole or
565 indazole ring to any extent, whether or not substituted on the
566 naphthyl ring to any extent, including, but not limited to:
567 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
568 carboxylate).
569 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
570 carboxylate).
571 (III) Fluoro SDB-005 (1-Naphthalenyl 1
572 (fluoropentyl)indazole-3-carboxylate).
573 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
574 carboxylate).
575 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
576 carboxylate).
577 l. Naphthylindole carboxamides and Naphthylindazole
578 carboxamides.—Any compound containing a naphthylindole
579 carboxamide or naphthylindazole carboxamide structure, with or
580 without substitution on the indole or indazole ring to any
581 extent, whether or not substituted on the naphthyl ring to any
582 extent, including, but not limited to:
583 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
584 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
585 3-carboxamide).
586 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
587 (chloropentyl)indole-3-carboxamide).
588 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
589 carboxamide).
590 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
591 (fluoropentyl)indazole-3-carboxamide).
592 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
593 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
594 Alkylcarbonyl indazole carboxylates.—Any compound containing an
595 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
596 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
597 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
598 indole carboxamide, indazole carboxamide, indole carboxylate, or
599 indazole carboxylate, with or without substitution on the indole
600 or indazole ring to any extent, whether or not substituted on
601 the alkylcarbonyl group to any extent, including, but not
602 limited to:
603 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
604 pentylindole-3-carboxamide).
605 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
606 yl)-1-(fluoropentyl)indole-3-carboxamide).
607 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
608 (fluoropentyl)indole-3-carboxamide).
609 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
610 pentylindazole-3-carboxamide).
611 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
612 1-(fluoropentyl)indazole-3-carboxamide).
613 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
614 1-pentylindazole-3-carboxamide).
615 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
616 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
617 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
618 (4-fluorobenzyl)indazole-3-carboxamide).
619 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
620 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
621 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
622 (cyclohexylmethyl)indazole-3-carboxamide).
623 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
624 (cyclohexylmethyl)indazole-3-carboxamide).
625 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
626 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
627 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
628 pentylindazole-3-carboxamide).
629 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
630 (fluoropentyl)indazole-3-carboxamide).
631 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
632 fluorobenzyl)indazole-3-carboxamide).
633 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
634 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
635 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
636 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
637 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
638 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
639 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
640 fluoropentyl)indole-3-carboxamide).
641 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
642 fluoropentyl)indazole-3-carboxamide).
643 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
644 (cyclohexylmethyl)indazole-3-carboxamide).
645 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
646 fluorobenzyl)indazole-3-carboxamide).
647 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
648 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
649 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
650 Any compound containing a N-(2-phenylpropan-2-yl) indole
651 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
652 structure, with or without substitution on the indole or
653 indazole ring to any extent, whether or not substituted on the
654 phenyl ring of the cumyl group to any extent, including, but not
655 limited to:
656 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
657 carboxamide).
658 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
659 (fluoropentyl)indole-3-carboxamide).
660 o. Other Synthetic Cannabinoids.—Any material, compound,
661 mixture, or preparation that contains any quantity of a
662 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
663 (I) With or without modification or replacement of a
664 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
665 between either two core rings, or linkage between a core ring
666 and group structure, with or without the addition of a carbon or
667 replacement of a carbon;
668 (II) With or without replacement of a core ring or group
669 structure, whether or not substituted on the ring or group
670 structures to any extent; and
671 (III) Is a cannabinoid receptor agonist, unless
672 specifically excepted or unless listed in another schedule or
673 contained within a pharmaceutical product approved by the United
674 States Food and Drug Administration.
675 191. Substituted Cathinones.—Unless specifically excepted,
676 listed in another schedule, or contained within a pharmaceutical
677 product approved by the United States Food and Drug
678 Administration, any material, compound, mixture, or preparation,
679 including its salts, isomers, esters, or ethers, and salts of
680 isomers, esters, or ethers, whenever the existence of such salts
681 is possible within any of the following specific chemical
682 designations:
683 a. Any compound containing a 2-amino-1-phenyl-1-propanone
684 structure;
685 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
686 structure; or
687 c. Any compound containing a 2-amino-1-thiophenyl-1
688 propanone structure,
689
690 whether or not the compound is further modified:
691 (I) With or without substitution on the ring system to any
692 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
693 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
694 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
695 substituents;
696 (II) With or without substitution at the 3-propanone
697 position with an alkyl substituent or removal of the methyl
698 group at the 3-propanone position;
699 (III) With or without substitution at the 2-amino nitrogen
700 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
701 not further substituted in the ring system; or
702 (IV) With or without inclusion of the 2-amino nitrogen atom
703 in a cyclic structure, including, but not limited to:
704 (A) Methcathinone.
705 (B) Ethcathinone.
706 (C) Methylone (3,4-Methylenedioxymethcathinone).
707 (D) 2,3-Methylenedioxymethcathinone.
708 (E) MDPV (3,4-Methylenedioxypyrovalerone).
709 (F) Methylmethcathinone.
710 (G) Methoxymethcathinone.
711 (H) Fluoromethcathinone.
712 (I) Methylethcathinone.
713 (J) Butylone (3,4-Methylenedioxy-alpha
714 methylaminobutyrophenone).
715 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
716 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
717 (M) Naphyrone (Naphthylpyrovalerone).
718 (N) Bromomethcathinone.
719 (O) Buphedrone (alpha-Methylaminobutyrophenone).
720 (P) Eutylone (3,4-Methylenedioxy-alpha
721 ethylaminobutyrophenone).
722 (Q) Dimethylcathinone.
723 (R) Dimethylmethcathinone.
724 (S) Pentylone (3,4-Methylenedioxy-alpha
725 methylaminovalerophenone).
726 (T) Pentedrone (alpha-Methylaminovalerophenone).
727 (U) MDPPP (3,4-Methylenedioxy-alpha
728 pyrrolidinopropiophenone).
729 (V) MDPBP (3,4-Methylenedioxy-alpha
730 pyrrolidinobutyrophenone).
731 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
732 (X) PPP (Pyrrolidinopropiophenone).
733 (Y) PVP (Pyrrolidinovalerophenone) or
734 (Pyrrolidinopentiophenone).
735 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
736 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
737 (BB) F-MABP (Fluoromethylaminobutyrophenone).
738 (CC) Me-EABP (Methylethylaminobutyrophenone).
739 (DD) PBP (Pyrrolidinobutyrophenone).
740 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
741 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
742 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
743 (HH) Dimethylone (3,4-Methylenedioxy-N,N
744 dimethylcathinone).
745 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
746 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
747 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
748 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
749 (MM) Methylbuphedrone (Methyl-alpha
750 methylaminobutyrophenone).
751 (NN) Methyl-alpha-methylaminohexanophenone.
752 (OO) N-Ethyl-N-methylcathinone.
753 (PP) PHP (Pyrrolidinohexanophenone).
754 (QQ) PV8 (Pyrrolidinoheptanophenone).
755 (RR) Chloromethcathinone.
756 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
757 192. Substituted Phenethylamines.—Unless specifically
758 excepted or unless listed in another schedule, or contained
759 within a pharmaceutical product approved by the United States
760 Food and Drug Administration, any material, compound, mixture,
761 or preparation, including its salts, isomers, esters, or ethers,
762 and salts of isomers, esters, or ethers, whenever the existence
763 of such salts is possible within any of the following specific
764 chemical designations, any compound containing a phenethylamine
765 structure, without a beta-keto group, and without a benzyl group
766 attached to the amine group, whether or not the compound is
767 further modified with or without substitution on the phenyl ring
768 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
769 halide, fused alkylenedioxy, fused furan, fused benzofuran,
770 fused dihydrofuran, or fused tetrahydropyran substituents,
771 whether or not further substituted on a ring to any extent, with
772 or without substitution at the alpha or beta position by any
773 alkyl substituent, with or without substitution at the nitrogen
774 atom, and with or without inclusion of the 2-amino nitrogen atom
775 in a cyclic structure, including, but not limited to:
776 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
777 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
778 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
779 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
780 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
781 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
782 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
783 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
784 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
785 j. 2C-H (2,5-Dimethoxyphenethylamine).
786 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
787 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
788 m. MDMA (3,4-Methylenedioxymethamphetamine).
789 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
790 Methylenedioxy-N-methylbutanamine).
791 o. MDA (3,4-Methylenedioxyamphetamine).
792 p. 2,5-Dimethoxyamphetamine.
793 q. Fluoroamphetamine.
794 r. Fluoromethamphetamine.
795 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
796 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
797 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
798 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
799 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
800 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
801 y. PMA (4-Methoxyamphetamine).
802 z. N-Ethylamphetamine.
803 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
804 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
805 cc. PMMA (4-Methoxymethamphetamine).
806 dd. N,N-Dimethylamphetamine.
807 ee. 3,4,5-Trimethoxyamphetamine.
808 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
809 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
810 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
811 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
812 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
813 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
814 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
815 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
816 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
817 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
818 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
819 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
820 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
821 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
822 dihydrobenzofuran),
823
824 which does not include phenethylamine, mescaline as described in
825 subparagraph 20., substituted cathinones as described in
826 subparagraph 191., N-Benzyl phenethylamine compounds as
827 described in subparagraph 193., or methamphetamine as described
828 in subparagraph (2)(c)5.
829 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
830 excepted or unless listed in another schedule, or contained
831 within a pharmaceutical product approved by the United States
832 Food and Drug Administration, any material, compound, mixture,
833 or preparation, including its salts, isomers, esters, or ethers,
834 and salts of isomers, esters, or ethers, whenever the existence
835 of such salts is possible within any of the following specific
836 chemical designations, any compound containing a phenethylamine
837 structure without a beta-keto group, with substitution on the
838 nitrogen atom of the amino group with a benzyl substituent, with
839 or without substitution on the phenyl or benzyl ring to any
840 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
841 alkylenedioxy, fused furan, fused benzofuran, or fused
842 tetrahydropyran substituents, whether or not further substituted
843 on a ring to any extent, with or without substitution at the
844 alpha position by any alkyl substituent, including, but not
845 limited to:
846 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
847 methoxybenzyl)]phenethylamine).
848 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
849 hydroxybenzyl)]phenethylamine).
850 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
851 fluorobenzyl)]phenethylamine).
852 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
853 methylenedioxybenzyl)]phenethylamine).
854 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
855 methoxybenzyl)]phenethylamine).
856 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
857 hydroxybenzyl)]phenethylamine).
858 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
859 fluorobenzyl)]phenethylamine).
860 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
861 methylenedioxybenzyl)]phenethylamine).
862 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
863 methoxybenzyl)]phenethylamine).
864 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
865 methoxybenzyl)]phenethylamine).
866 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
867 methoxybenzyl)]phenethylamine).
868 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
869 methoxybenzyl)]phenethylamine).
870 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
871 hydroxybenzyl)]phenethylamine).
872 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
873 fluorobenzyl)]phenethylamine).
874 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
875 methylenedioxybenzyl)]phenethylamine).
876 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
877 methoxybenzyl)]phenethylamine).
878 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
879 hydroxybenzyl)]phenethylamine).
880 r. 25H-NBF (2,5-Dimethoxy-[N-(2
881 fluorobenzyl)]phenethylamine).
882 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
883 methoxybenzyl)]phenethylamine),
884
885 which does not include substituted cathinones as described in
886 subparagraph 191.
887 194. Substituted Tryptamines.—Unless specifically excepted
888 or unless listed in another schedule, or contained within a
889 pharmaceutical product approved by the United States Food and
890 Drug Administration, any material, compound, mixture, or
891 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
892 example tryptamine, structure with or without mono- or di
893 substitution of the amine nitrogen with alkyl or alkenyl groups,
894 or by inclusion of the amino nitrogen atom in a cyclic
895 structure, whether or not substituted at the alpha position with
896 an alkyl group, whether or not substituted on the indole ring to
897 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
898 groups, including, but not limited to:
899 a. Alpha-Ethyltryptamine.
900 b. Bufotenine.
901 c. DET (Diethyltryptamine).
902 d. DMT (Dimethyltryptamine).
903 e. MET (N-Methyl-N-ethyltryptamine).
904 f. DALT (N,N-Diallyltryptamine).
905 g. EiPT (N-Ethyl-N-isopropyltryptamine).
906 h. MiPT (N-Methyl-N-isopropyltryptamine).
907 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
908 j. 5-Hydroxy-N-methyltryptamine.
909 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
910 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
911 m. Methyltryptamine.
912 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
913 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
914 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
915 q. DiPT (N,N-Diisopropyltryptamine).
916 r. DPT (N,N-Dipropyltryptamine).
917 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
918 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
919 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
920 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
921 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
922 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
923 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
924 isopropyltryptamine).
925 z. Methyl-alpha-ethyltryptamine.
926 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
927
928 which does not include tryptamine, psilocyn as described in
929 subparagraph 34., or psilocybin as described in subparagraph 33.
930 195. Substituted Phenylcyclohexylamines.—Unless
931 specifically excepted or unless listed in another schedule, or
932 contained within a pharmaceutical product approved by the United
933 States Food and Drug Administration, any material, compound,
934 mixture, or preparation containing a phenylcyclohexylamine
935 structure, with or without any substitution on the phenyl ring,
936 any substitution on the cyclohexyl ring, any replacement of the
937 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
938 without substitution on the amine with alkyl, dialkyl, or alkoxy
939 substituents, inclusion of the nitrogen in a cyclic structure,
940 or any combination of the above, including, but not limited to:
941 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
942 (Benocyclidine).
943 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
944 of phencyclidine).
945 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
946 analog of phencyclidine).
947 d. PCPr (Phenylcyclohexylpropylamine).
948 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
949 analog of phencyclidine).
950 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
951 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
952 h. Methoxetamine.
953 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
954 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
955 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
956 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
957 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
958 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
959 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
960 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
961 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
962 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
963 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
964 piperidinylidene]-benzenesulfonamide.
965 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
966 piperidinylidene]-benzenesulfonamide.
967 198. AH-7921, 3,4-dichloro-N-[[1
968 (dimethylamino)cyclohexyl]methyl]-benzamide.
969 199. U47700, trans-3,4-dichloro-N-[2
970 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
971 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
972 dihydrochloride.
973 Section 2. Paragraph (i) of subsection (1) of section
974 893.13, Florida Statutes, is amended to read:
975 893.13 Prohibited acts; penalties.—
976 (1)
977 (i) Except as authorized by this chapter, a person commits
978 a felony of the first degree, punishable as provided in s.
979 775.082, s. 775.083, or s. 775.084, and must be sentenced to a
980 mandatory minimum term of imprisonment of 3 years, if:
981 1. The person sells, manufactures, or delivers, or
982 possesses with intent to sell, manufacture, or deliver, any of
983 the following:
984 a. Alfentanil, as described in s. 893.03(2)(b)1.;
985 b. Carfentanil, as described in s. 893.03(2)(b)6.;
986 c. Fentanyl, as described in s. 893.03(2)(b)9.;
987 d. Sufentanil, as described in s. 893.03(2)(b)30.;
988 e. A fentanyl derivative, as described in s.
989 893.03(1)(a)63.;
990 f. Xylazine, as described in s. 893.03(1)(c)37.;
991 g.f. A controlled substance analog, as described in s.
992 893.0356, of any substance described in sub-subparagraphs a.-f.
993 sub-subparagraphs a.-e.; or
994 h.g. A mixture containing any substance described in sub
995 subparagraphs a.-g. sub-subparagraphs a.-f.; and
996 2. The substance or mixture listed in subparagraph 1. is in
997 a form that resembles, or is mixed, granulated, absorbed, spray
998 dried, or aerosolized as or onto, coated on, in whole or in
999 part, or solubilized with or into, a product, when such product
1000 or its packaging further has at least one of the following
1001 attributes:
1002 a. Resembles the trade dress of a branded food product,
1003 consumer food product, or logo food product;
1004 b. Incorporates an actual or fake registered copyright,
1005 service mark, or trademark;
1006 c. Resembles candy, cereal, a gummy, a vitamin, or a
1007 chewable product, such as a gum or gelatin-based product; or
1008 d. Contains a cartoon character imprint.
1009 Section 3. Paragraph (c) of subsection (1) of section
1010 893.135, Florida Statutes, is amended to read:
1011 893.135 Trafficking; mandatory sentences; suspension or
1012 reduction of sentences; conspiracy to engage in trafficking.—
1013 (1) Except as authorized in this chapter or in chapter 499
1014 and notwithstanding the provisions of s. 893.13:
1015 (c)1. A person who knowingly sells, purchases,
1016 manufactures, delivers, or brings into this state, or who is
1017 knowingly in actual or constructive possession of, 4 grams or
1018 more of any morphine, opium, hydromorphone, or any salt,
1019 derivative, isomer, or salt of an isomer thereof, including
1020 heroin, as described in s. 893.03(1)(b), (2)(a), (3)(c)3., or
1021 (3)(c)4., or 4 grams or more of any mixture containing any such
1022 substance, but less than 30 kilograms of such substance or
1023 mixture, commits a felony of the first degree, which felony
1024 shall be known as “trafficking in illegal drugs,” punishable as
1025 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1026 quantity involved:
1027 a. Is 4 grams or more, but less than 14 grams, such person
1028 shall be sentenced to a mandatory minimum term of imprisonment
1029 of 3 years and shall be ordered to pay a fine of $50,000.
1030 b. Is 14 grams or more, but less than 28 grams, such person
1031 shall be sentenced to a mandatory minimum term of imprisonment
1032 of 15 years and shall be ordered to pay a fine of $100,000.
1033 c. Is 28 grams or more, but less than 30 kilograms, such
1034 person shall be sentenced to a mandatory minimum term of
1035 imprisonment of 25 years and shall be ordered to pay a fine of
1036 $500,000.
1037 2. A person who knowingly sells, purchases, manufactures,
1038 delivers, or brings into this state, or who is knowingly in
1039 actual or constructive possession of, 28 grams or more of
1040 hydrocodone, as described in s. 893.03(2)(a)1.k., codeine, as
1041 described in s. 893.03(2)(a)1.g., or any salt thereof, or 28
1042 grams or more of any mixture containing any such substance,
1043 commits a felony of the first degree, which felony shall be
1044 known as “trafficking in hydrocodone,” punishable as provided in
1045 s. 775.082, s. 775.083, or s. 775.084. If the quantity involved:
1046 a. Is 28 grams or more, but less than 50 grams, such person
1047 shall be sentenced to a mandatory minimum term of imprisonment
1048 of 3 years and shall be ordered to pay a fine of $50,000.
1049 b. Is 50 grams or more, but less than 100 grams, such
1050 person shall be sentenced to a mandatory minimum term of
1051 imprisonment of 7 years and shall be ordered to pay a fine of
1052 $100,000.
1053 c. Is 100 grams or more, but less than 300 grams, such
1054 person shall be sentenced to a mandatory minimum term of
1055 imprisonment of 15 years and shall be ordered to pay a fine of
1056 $500,000.
1057 d. Is 300 grams or more, but less than 30 kilograms, such
1058 person shall be sentenced to a mandatory minimum term of
1059 imprisonment of 25 years and shall be ordered to pay a fine of
1060 $750,000.
1061 3. A person who knowingly sells, purchases, manufactures,
1062 delivers, or brings into this state, or who is knowingly in
1063 actual or constructive possession of, 7 grams or more of
1064 oxycodone, as described in s. 893.03(2)(a)1.q., or any salt
1065 thereof, or 7 grams or more of any mixture containing any such
1066 substance, commits a felony of the first degree, which felony
1067 shall be known as “trafficking in oxycodone,” punishable as
1068 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1069 quantity involved:
1070 a. Is 7 grams or more, but less than 14 grams, such person
1071 shall be sentenced to a mandatory minimum term of imprisonment
1072 of 3 years and shall be ordered to pay a fine of $50,000.
1073 b. Is 14 grams or more, but less than 25 grams, such person
1074 shall be sentenced to a mandatory minimum term of imprisonment
1075 of 7 years and shall be ordered to pay a fine of $100,000.
1076 c. Is 25 grams or more, but less than 100 grams, such
1077 person shall be sentenced to a mandatory minimum term of
1078 imprisonment of 15 years and shall be ordered to pay a fine of
1079 $500,000.
1080 d. Is 100 grams or more, but less than 30 kilograms, such
1081 person shall be sentenced to a mandatory minimum term of
1082 imprisonment of 25 years and shall be ordered to pay a fine of
1083 $750,000.
1084 4.a. A person who knowingly sells, purchases, manufactures,
1085 delivers, or brings into this state, or who is knowingly in
1086 actual or constructive possession of, 4 grams or more of:
1087 (I) Alfentanil, as described in s. 893.03(2)(b)1.;
1088 (II) Carfentanil, as described in s. 893.03(2)(b)6.;
1089 (III) Fentanyl, as described in s. 893.03(2)(b)9.;
1090 (IV) Sufentanil, as described in s. 893.03(2)(b)30.;
1091 (V) A fentanyl derivative, as described in s.
1092 893.03(1)(a)63.;
1093 (VI) A controlled substance analog, as described in s.
1094 893.0356, of any substance described in sub-sub-subparagraphs
1095 (I)-(V); or
1096 (VII) A mixture containing any substance described in sub
1097 sub-subparagraphs (I)-(VI),
1098
1099 commits a felony of the first degree, which felony shall be
1100 known as “trafficking in dangerous fentanyl or fentanyl
1101 analogues,” punishable as provided in s. 775.082, s. 775.083, or
1102 s. 775.084.
1103 b. If the quantity involved under sub-subparagraph a.:
1104 (I) Is 4 grams or more, but less than 14 grams, such person
1105 shall be sentenced to a mandatory minimum term of imprisonment
1106 of 7 years, and shall be ordered to pay a fine of $50,000.
1107 (II) Is 14 grams or more, but less than 28 grams, such
1108 person shall be sentenced to a mandatory minimum term of
1109 imprisonment of 20 years, and shall be ordered to pay a fine of
1110 $100,000.
1111 (III) Is 28 grams or more, such person shall be sentenced
1112 to a mandatory minimum term of imprisonment of 25 years, and
1113 shall be ordered to pay a fine of $500,000.
1114 c. A person 18 years of age or older who violates sub
1115 subparagraph a. by knowingly selling or delivering to a minor at
1116 least 4 grams of a substance or mixture listed in sub
1117 subparagraph a. shall be sentenced to a mandatory minimum term
1118 of not less than 25 years and not exceeding life imprisonment,
1119 and shall be ordered to pay a fine of $1 million if the
1120 substance or mixture listed in sub-subparagraph a. is in a form
1121 that resembles, or is mixed, granulated, absorbed, spray-dried,
1122 or aerosolized as or onto, coated on, in whole or in part, or
1123 solubilized with or into, a product, when such product or its
1124 packaging further has at least one of the following attributes:
1125 (I) Resembles the trade dress of a branded food product,
1126 consumer food product, or logo food product;
1127 (II) Incorporates an actual or fake registered copyright,
1128 service mark, or trademark;
1129 (III) Resembles candy, cereal, a gummy, a vitamin, or a
1130 chewable product, such as a gum or gelatin-based product; or
1131 (IV) Contains a cartoon character imprint.
1132 5. A person who knowingly sells, purchases, manufactures,
1133 delivers, or brings into this state, or who is knowingly in
1134 actual or constructive possession of, 30 kilograms or more of
1135 any morphine, opium, oxycodone, hydrocodone, codeine,
1136 hydromorphone, or any salt, derivative, isomer, or salt of an
1137 isomer thereof, including heroin, as described in s.
1138 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or 30 kilograms or
1139 more of any mixture containing any such substance, commits the
1140 first degree felony of trafficking in illegal drugs. A person
1141 who has been convicted of the first degree felony of trafficking
1142 in illegal drugs under this subparagraph shall be punished by
1143 life imprisonment and is ineligible for any form of
1144 discretionary early release except pardon or executive clemency
1145 or conditional medical release under s. 947.149. However, if the
1146 court determines that, in addition to committing any act
1147 specified in this paragraph:
1148 a. The person intentionally killed an individual or
1149 counseled, commanded, induced, procured, or caused the
1150 intentional killing of an individual and such killing was the
1151 result; or
1152 b. The person’s conduct in committing that act led to a
1153 natural, though not inevitable, lethal result,
1154
1155 such person commits the capital felony of trafficking in illegal
1156 drugs, punishable as provided in ss. 775.082 and 921.142. A
1157 person sentenced for a capital felony under this paragraph shall
1158 also be sentenced to pay the maximum fine provided under
1159 subparagraph 1.
1160 6. A person who knowingly brings into this state 60
1161 kilograms or more of any morphine, opium, oxycodone,
1162 hydrocodone, codeine, hydromorphone, or any salt, derivative,
1163 isomer, or salt of an isomer thereof, including heroin, as
1164 described in s. 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or
1165 60 kilograms or more of any mixture containing any such
1166 substance, and who knows that the probable result of such
1167 importation would be the death of a person, commits capital
1168 importation of illegal drugs, a capital felony punishable as
1169 provided in ss. 775.082 and 921.142. A person sentenced for a
1170 capital felony under this paragraph shall also be sentenced to
1171 pay the maximum fine provided under subparagraph 1.
1172 7. A person who knowingly sells, purchases, manufactures,
1173 delivers, or brings into this state, or who is knowingly in
1174 actual or constructive possession of, 28 grams or more of
1175 xylazine, as described in s. 893.03(1)(c)37., or any salt
1176 thereof, or 28 grams or more of any mixture containing any such
1177 substance, commits a felony of the first degree, which felony
1178 shall be known as “trafficking in xylazine,” punishable as
1179 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1180 quantity involved:
1181 a. Is 28 grams or more, but less than 100 grams, such
1182 person shall be sentenced to a mandatory minimum term of
1183 imprisonment of 3 years and shall be ordered to pay a fine of
1184 $50,000.
1185 b. Is 100 grams or more, but less than 200 grams, such
1186 person shall be sentenced to a mandatory minimum term of
1187 imprisonment of 7 years and shall be ordered to pay a fine of
1188 $100,000.
1189 c. Is 200 grams or more, such person shall be sentenced to
1190 a mandatory minimum term of imprisonment of 25 years and shall
1191 be ordered to pay a fine of $500,000.
1192 Section 4. Except as otherwise expressly provided in this
1193 act and except for this section, which shall take effect upon
1194 this act becoming a law, this act shall take effect October 1,
1195 2026.
1196
1197 ================= T I T L E A M E N D M E N T ================
1198 And the title is amended as follows:
1199 Delete everything before the enacting clause
1200 and insert:
1201 A bill to be entitled
1202 An act relating to controlled substances; amending s.
1203 893.03, F.S.; excepting from the list of Schedule I
1204 controlled substances certain xylazine animal drug
1205 products approved by the United States Food and Drug
1206 Administration and used for certain purposes; amending
1207 s. 893.13, F.S.; providing criminal penalties and
1208 requiring a mandatory minimum term of imprisonment if
1209 a person sells, manufactures, or delivers or possesses
1210 with intent to sell, manufacture, or deliver xylazine;
1211 amending s. 893.135, F.S.; creating the offense of
1212 trafficking in xylazine; providing criminal penalties
1213 and requiring a mandatory minimum term of imprisonment
1214 and fines based on the quantity of the controlled
1215 substance involved in the offense; providing effective
1216 dates.